Table 3.
Comparison of clinical and laboratory investigations at baseline and 3 months later in control group
| Parameter | Baseline, n = 100 |
3 months later, n = 100
|
Test of sig.
|
|||
|
t
|
P value
|
|||||
| Mean | SD | Mean | SD | |||
| Body weight in kg | 95.86 | 19.13 | 84.60 | 14.21 | 4.725 | 0.0001 |
| BMI in kg/m2 | 33.45 | 6.08 | 29.54 | 5.29 | 4.86 | 0.0001 |
| SBP in mmHg | 112.00 | 15.04 | 111.20 | 12.97 | 0.403 | 0.688 |
| DBP in mmHg | 70.80 | 10.22 | 70.80 | 9.18 | 0.0001 | 0.999 |
| HbA1c as % | 10.22 | 2.03 | 7.47 | 1.11 | 11.9 | 0.0001 |
| Fasting blood sugar in mg/dL | 299.26 | 77.57 | 174.74 | 63.29 | 12.438 | 0.0001 |
| Triglycerides in mg/dL | 240.04 | 78.18 | 221.62 | 51.48 | 1.968 | 0.050 |
| Cholesterol in mg/dL | 230.20 | 77.26 | 223.64 | 79.44 | 0.592 | 0.555 |
| Creatinine in mg/dL | 0.98 | 0.44 | 0.99 | 0.57 | -0.144 | 0.886 |
| MELD | 12.46 | 5.11 | 12.32 | 5.60 | 0.185 | 0.854 |
| MELD-Na | 17.46 | 6.72 | 16.70 | 7.08 | 0.778 | 0.437 |
| eGFR value in mL/min/1.73 m2 | 119.29 | 68.19 | 101.53 | 46.25 | 2.141 | 0.034 |
| Uric acid in mg/dL | 4.96 | 0.80 | 4.96 | 0.80 | 0.0001 | 0.999 |
| AST in IU/L | 74.56 | 90.09 | 67.58 | 81.21 | 0.575 | 0.566 |
| ALT in IU/L | 40.40 | 30.79 | 41.72 | 31.73 | -0.299 | 0.766 |
| GGT in IU/L | 131.98 | 199.44 | 131.31 | 269.69 | 0.02 | 0.984 |
| Serum Na in mmol/L | 131.42 | 5.81 | 131.36 | 6.78 | 0.067 | 0.946 |
| Serum K in mg/dL | 4.33 | 0.62 | 4.19 | 0.45 | 1.857 | 0.065 |
ALT: Alanine transaminase; AST: Aspartate aminotransferase; BMI: Body mass index; DBP: Diastolic blood pressure; eGFR: Estimated glomerular filtration rate; GGT: gamma-glutamyl transferase; HbA1c: Hemoglobin A1c; K: Potassium; MELD: Model for end-stage liver disease; MELD-Na: Model for end-stage liver disease-sodium; NA: Sodium; SBP: Systolic blood pressure.